Back

Refining tricuspid regurgitation grading: do mild-to-moderate and moderate-to-severe categories improve mortality prediction in heart failure patients?

29 August 2025 (13:15 - 14:00)
Organised by: Logo
Congress Presentation Part of: Functional and anatomical features in aortic valve disease Imaging ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Isabel Mattig

German Heart Centre Berlin, Berlin (Germany)

7 More presentations in this session

Presentation thumbnail
Quantitative approaches to tricuspid valve regurgitation severity: identifying the most reliable method
Doctor I. Navarro-Pelayo Torres (Granada, ES)
Abstract Slides Video
Presentation thumbnail
Sex-related differences in cardiac remodeling after mitral valve surgery: when the right goes wrong
Doctor C. Mancebo (Madrid, ES)
Abstract Slides Video
Presentation thumbnail
Predictors of ascending aortic dilation in patients with bicuspid aortic valve
Professor Y. He (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Threshold values of the vena contracta area for grading secondary tricuspid regurgitation and its association with outcomes
Doctor G. Benzoni (Milan, IT)
Abstract Slides Video
Presentation thumbnail
Improving the quantitative assessment of tricuspid regurgitation severity by establishing new threshold values for the corrected proximal isovelocity surface area method
Doctor A. Buta (Bucharest, RO)
Abstract Slides Video

Access the full session

Session thumbnail
Functional and anatomical features in aortic valve disease

The Event

Event poster

ESC Congress 2025

29 August 2025 13:15 CET
You may be interested in
thumbnail
Congress Presentation
Refining the assessment of moderate secondary tricuspid regurgitation: an echocardiographic approach to risk stratification
thumbnail
Congress Session
Focus on tricuspid regurgitation!
thumbnail
Congress Presentation
Too little, too late: atrial secondary tricuspid regurgitation (A-STR) carries a better prognosis in early-stage heart failure, but not in late-stage

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources